Specifically, positive mutant KRAS–ctDNA status has been associated with earlier tumour recurrence, greater metastatic burden, and shorter median progression-free survival (mPFS) and median overall survival (mOS) [37,39,40,41,56,57,58]. Here, KRAS is linked to neoplasm.